<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width,initial-scale=1" />
<title>ILC vs IDC — Clinical, Molecular & Therapeutic Differences</title>
<style>
  :root{
    --bg:#0f172a;          
    --card:#111827;        
    --ink:#e5e7eb;         
    --muted:#94a3b8;       
    --ilc:#f59e0b;         
    --idc:#60a5fa;         
    --good:#10b981;        
    --warn:#f43f5e;        
    --row:#0b1223;         
  }
  *{box-sizing:border-box}
  body{
    margin:0; padding:28px;
    background:linear-gradient(135deg,#0b1020 0%, #0f172a 50%, #0b1020 100%);
    font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Apple Color Emoji","Segoe UI Emoji";
    color:var(--ink); line-height:1.45;
  }
  .wrap{max-width:1100px; margin:0 auto; border-radius:20px; overflow:hidden;}
  header{
    padding:22px; display:flex; align-items:center; justify-content:space-between; gap:12px;
    background: radial-gradient(1200px 200px at 20% -40%, rgba(245,158,11,.15), transparent 70%),
               radial-gradient(900px 180px at 90% -30%, rgba(96,165,250,.15), transparent 70%);
    border-bottom:1px solid rgba(148,163,184,.25);
  }
  .title{font-size:22px; font-weight:800; letter-spacing:.2px;}
  .chips{display:flex; gap:8px; flex-wrap:wrap}
  .chip{border:1px solid rgba(148,163,184,.3); padding:6px 10px; border-radius:999px; font-size:12px; color:var(--muted);}
  .legend{display:flex; gap:8px; align-items:center}
  .badge{display:inline-flex; align-items:center; gap:6px; font-weight:700; padding:6px 10px; border-radius:10px; font-size:12px;}
  .badge.ilc{background: linear-gradient(135deg,#fde68a,#f59e0b); color:#1f2937}
  .badge.idc{background: linear-gradient(135deg,#93c5fd,#3b82f6); color:#0b1020}
  table{width:100%; border-collapse:separate; border-spacing:0;}
  th, td{padding:14px 16px; vertical-align:top; border-bottom:1px solid rgba(148,163,184,.18);}
  thead th{position:sticky; top:0; background:rgba(17,24,39,.9); text-align:left; font-size:14px;}
  tbody tr:nth-child(odd){ background: var(--row);}
  .col-label{width:28%}
  .col-ilc, .col-idc{width:36%}
  .pill{display:inline-flex; align-items:center; gap:6px; border-radius:999px; padding:2px 8px; font-size:12px; font-weight:700;}
  .pill.good{background: rgba(16,185,129,.12); border:1px solid rgba(16,185,129,.35)}
  .pill.warn{background: rgba(244,63,94,.12); border:1px solid rgba(244,63,94,.35)}
  .ref{padding:14px 22px; color:var(--muted); font-size:12px}
  .back a{display:inline-block; margin:12px; padding:8px 12px; border-radius:8px;
    border:1px solid rgba(148,163,184,.35); background:#111827; color:#93c5fd; text-decoration:none;}
  .back a:hover{background:#0b1223; text-decoration:underline}
</style>
</head>
<body>
  <div class="wrap">
    <header>
      <div>
        <div class="title">ILC vs IDC — Differences & Therapeutic Implications</div>
        <div class="chips">
          <span class="chip">🧬 CDH1 / E-cadherin</span>
          <span class="chip">🌸 ER-positive predominance</span>
          <span class="chip">💊 AI & Trastuzumab decisions</span>
          <span class="chip">🧭 Metastatic tropism</span>
        </div>
      </div>
      <div class="legend">
        <span class="badge ilc">🟡 ILC</span>
        <span class="badge idc">🔵 IDC</span>
      </div>
    </header>

    <!-- Back-link -->
    <p class="back"><a href="index.html">⬅︎ Back to Surgery Home</a></p>

    <table role="table" aria-label="ILC vs IDC Comparison">
      <thead>
        <tr>
          <th class="col-label">🧩 Category</th>
          <th class="col-ilc">🟡 ILC</th>
          <th class="col-idc">🔵 IDC</th>
          <th>🎯 Therapeutic Implications</th>
        </tr>
      </thead>
      <tbody>
        <!-- Clinical Presentation row at top -->
        <tr>
          <td>🩺 Example Clinical Presentation</td>
          <td>👵 Postmeno, ER+ mass; subtle/asymmetric thickening (often underestimated on 🩻 mammogram); later GI/peritoneal spread 🫄</td>
          <td>🤏 Palpable spiculated lump; clear imaging correlate; later 🦴 bone pain</td>
          <td>🧭 ILC: order <b>MRI</b> for accurate extent, endocrine-first in many cases</td>
        </tr>

        <tr>
          <td>📊 Prevalence</td>
          <td>~10% of BCs</td>
          <td>Most common subtype</td>
          <td>📝 ILC underrepresented in trials → don’t assume IDC data applies</td>
        </tr>

        <tr>
          <td>🔬 Morphology</td>
          <td>“<b>Single-file</b>” 🧵 cells; hallmark = <b>E-cadherin loss</b> 🚫</td>
          <td>Cohesive nests/glands 🧱</td>
          <td>Loss of cohesion = diffuse margins, hard to excise completely</td>
        </tr>

        <tr>
          <td>🧬 Genomics</td>
          <td>↑ CDH1, PTEN loss/AKT ↑, TBX3, FOXA1; ↓ GATA3 🧬</td>
          <td>More GATA3; rare CDH1</td>
          <td>Explains differential endocrine sensitivity/resistance</td>
        </tr>

        <tr>
          <td>🌸 Hormone/Proliferation</td>
          <td>Mostly ER+, HER2–; low Ki-67 🌿; Luminal A–like</td>
          <td>Mixed: Luminal A/B, HER2+, TNBC</td>
          <td><span class="pill good">Endocrine-driven</span> in ILC</td>
        </tr>

        <tr>
          <td>🧭 Spread</td>
          <td>GI 🍽️, peritoneum 🫄, ovaries 🥚</td>
          <td>Bone 🦴, lung 🌬️, liver 🧫</td>
          <td>Tailor staging/surveillance → look beyond classic bone/liver mets</td>
        </tr>

        <tr>
          <td>💉 Chemo Response</td>
          <td>Low pCR (~3–5%) ⚠️; less downstaging</td>
          <td>Higher pCR (~14%) ✅; more BCS possible</td>
          <td>Chemo sparingly in ILC; biomarker-driven approach</td>
        </tr>

        <tr>
          <td>🧪 Oncotype DX</td>
          <td>Rarely high RS (~1.5%); many intermediate 🤔</td>
          <td>Up to 20% high RS</td>
          <td>Intermediate less predictive in ILC → combine with pathology</td>
        </tr>

        <tr>
          <td>🧿 HER2 & Trastuzumab</td>
          <td>Classic ILC 3–5%; mixed up to ~10% ➕; trastuzumab works 💉</td>
          <td>15–20%; standard anti-HER2 therapy</td>
          <td>Don’t skip HER2 testing in ILC → benefit ≈ IDC</td>
        </tr>

        <tr>
          <td>🌡️ Endocrine Therapy</td>
          <td><b>AIs</b> (letrozole) better than TAM ➕🟢</td>
          <td>AI benefit clearest in Luminal B</td>
          <td>Postmeno ILC: <span class="pill good">AI first-line</span></td>
        </tr>

        <tr>
          <td>📉 Prognosis</td>
          <td>Slower growing ⏳ but risk of late recurrence; atypical mets patterns</td>
          <td>More chemo-sensitive, early downstaging 💥</td>
          <td>ILC: need MRI, wide margins, watch late relapse & GI mets</td>
        </tr>

        <tr>
          <td>🧠 Buzzwords</td>
          <td>“Single-file” 🧵 • “E-cadherin−” 🚫 • “GI mets” 🫄 • “AI>TAM” 💊</td>
          <td>“Cohesive glands” 🧱 • “GATA3” 🧬 • “Chemo-responsive” 💥</td>
          <td>Use for memory recall 🔑</td>
        </tr>
      </tbody>
    </table>

    <div class="ref">
      📚 Source: Barroso-Sousa R, Metzger-Filho O. <i>Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications.</i> PMCID: PMC4952020, PMID: 27482285.
    </div>
  </div>
</body>
</html>
